IMNN Imunon, Inc.

1.140USD+1.79%Mkt Cap: 6.40M $P/E: —

Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase…

Key Statistics

Company
Market Cap6.40M USD
Enterprise Value9.52M USD
Revenue (TTM)—
Gross Profit-409.92K USD
Net Income (TTM)-14.50M USD
Revenue/Share—
Last Price1.140 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees20
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.63
PEG5.03
EV/EBITDA-0.65
EV/Revenue—
P/S—
P/B2.70
EPS (TTM)-3.39
EPS (Forward)-1.77
52W Range
1.1001% of range5.550
52W High5.550 USD
52W Low1.100 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-205.26%
ROA-117.96%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-13.90M USD
CapEx (TTM)280.57K USD
FCF Margin—
FCF Yield-148.97%
Net Debt980.91K USD
Net Debt/EBITDA-0.07
Balance Sheet
Debt/Equity0.14
Current Ratio1.82
Quick Ratio1.44
Book Value/Sh0.41 USD
Cash/Share1.22 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split115:100
Split DateAug 7, 2025
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)17.00 USD
Upside (mean)+1391.2%
Target Range10.00 USD – 25.00 USD
10.00+1391.2% to mean25.00
# Analysts5
Ownership
Shares Out.5.61M
Float5.26M
Insiders6.06%
Institutions5.68%
Short Interest
Short Ratio1.8d
Short % Float3.47%
Short % Out.3.45%
Shares Short193.64K
Short (prev mo.)112.96K
Technical
SMA 501.510 (-24.5%)
SMA 2002.474 (-53.9%)
Beta2.00
S&P 52W Chg16.45%
Avg Vol (30d)129.16K
Avg Vol (10d)128.58K
Technical Indicators
RSI (14)29.0
MACD-0.1029
MACD Signal-0.0819
MACD Hist.-0.0210
BB Upper1.608 USD
BB Middle1.374 USD
BB Lower1.140 USD
BB Width34.13%
ATR (14)0.1118 USD
Vol Ratio (20d)0.65x